NDTV on MSN: Ozempic might preserve lean body mass better than Mounjaro: Study Morningstar: Lilly says Mounjaro and Zepbound sales more than doubled as stock rallied Lilly says Mounjaro and Zepbound sales more than doubled as stock rallied MarketWatch: Lilly says Mounjaro and Zepbound sales more than doubled, as stock rallies Lilly says Mounjaro and Zepbound sales more than doubled, as stock rallies Reuters on MSN: Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds The Indianapolis Star: Why tirzepatide is better than semaglutide, GLP-1 medication guide